At a glance
- Originator Pierre Fabre
- Class Neuroprotectants; Nootropics
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 29 Jun 2001 No-Development-Reported for Alzheimer's disease in France (Unknown route)
- 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance
- 09 Feb 1995 Preclinical development for Alzheimer's disease in France (Unknown route)